Morgan Stanley initiated coverage on Royalty Pharma with a new price target

5/16/25 8:05:49 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Morgan Stanley initiated coverage of Royalty Pharma with a rating of Overweight and set a new price target of $51.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RPRX

Date	Price Target	Rating	Analyst
5/16/2025	$51.00	Overweight	Morgan Stanley
6/3/2024	$28.00	Buy → Neutral	UBS
6/14/2022	$47.00	Buy	UBS
5/13/2022	$53.00	Sector Outperform	Scotiabank
4/27/2022	$56.00	Buy	Goldman
4/14/2022	$50.00	Neutral → Overweight	JP Morgan
4/6/2022	$48.00	Overweight	Morgan Stanley
10/29/2021	$50.00	Neutral → Buy	Citigroup